Detalhe da pesquisa
1.
Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia.
Haematologica
; 108(3): 747-760, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36263840
2.
Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.
J Transl Med
; 11: 187, 2013 Aug 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-23937772
3.
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.
J Immunother Cancer
; 11(8)2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37648261
4.
Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1).
BMC Cancer
; 12: 615, 2012 Dec 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-23259649
5.
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study.
J Hematol Oncol
; 15(1): 170, 2022 12 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36494725
6.
Antigen-specific in vitro expansion of functional redirected NY-ESO-1-specific human CD8+ T-cells in a cell-free system.
Anticancer Res
; 33(10): 4189-201, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24122982
7.
Induction of exosome release in primary B cells stimulated via CD40 and the IL-4 receptor.
J Immunol
; 180(12): 8146-52, 2008 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18523279